Recent news on Dacarbazine For

CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma  -  Apr 27, 2007
PR Newswire (press release),The MAA proposes the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The Company had previously announced its

Genta Incorporated announces phase 3 trial of Genasense in ...  -  Apr 20, 2007
News-Medical.net,The trial is designed to expand evidence for the safety and efficacy of Genasense combined with dacarbazine for patients who have not previously been

Genta Announces New Phase 3 Trial of Genasense(R) in Patients with ...  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),...to expand evidence for the safety and efficacy of Genasense combined with dacarbazine for patients who have not previously been treated with chemotherapy.

Genta Announces Closing of Common Stock Offering  -  Apr 4, 2007
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Genta Announces Expectation of a Negative Opinion from the CHMP on ...  -  Mar 23, 2007
PR-Inside.com (Pressemitteilung),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Phase 2 Results Of Genasense(R) Plus Chemotherapy In Advanced ...  -  Feb 24, 2007
Medical News Today (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Genta Incorporated Announces Fourth Quarter and Year End 2006 ...  -  Feb 13, 2007
Insurance News Net,Genta's Marketing Authorization Application (MAA) for the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma is currently

Genta Completes Response to EMEA List of Outstanding Issues for ...  -  Feb 7, 2007
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Pharma Sector: Few Newsmakers Of The Week - Exelixis, MGI Pharma ...  -  Feb 3, 2007
Trading Markets,The company's woes have been confounded by the rejection of its combination therapy of Genasense plus dacarbazine for the treatment of patients with

Pharma Sector: Few Newsmakers Of The Week - Opexa, J&J, Glaxo ...  -  Feb 11, 2007
Trading Markets,In 2004, the FDA advisory panel voted down the use of a combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced

Genta Restructures Operations to Focus on Future Initiatives  -  Dec 20, 2006
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane ...  -  Nov 29, 2006
PR Newswire (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,In 2004, the FDA advisory panel voted down the use of a combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced

Genasense Not Approvable' In CLL; Europe's Ruling Next  -  Dec 15, 2006
BioWorld Online,...the European Medicines Agency and expects word on whether marketing clearance will be granted to Genasense (oblimersen) plus dacarbazine for melanoma.

Genasense(R) Shown Active using Intermittent Dosing in Melanoma ...  09 Nov 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -Yahoo! News (press release) Genasense(R) Receives Orphan Drug Designation in Australia for ...  Oct 17, 2006
Application (MAA) that is currently under review with the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine for treatment of patients ... -PR Newswire (press release), Genta Gets Orphan Drug Designation In Australia For Genasense ...  Oct 17, 2006
...meanwhile, has filed Marketing Authorization Application or MAA with the European Medicines Agency for the use of Genasense plus dacarbazine for treatment of ... -Trading Markets, Genta's Gentasense gets orphan status  Oct 17, 2006
A marketing authorization application for the use of Genasense plus dacarbazine for treating patients with advanced melanoma is currently under review with the ... -United Press International Genta's Advanced Melanoma Drug, Genasense, Granted Orphan Drug ...  Oct 17, 2006
...addition, Genta has filed a Marketing Authorization Application with the European Medicines Agency, for the use of Genasense plus dacarbazine for treatment of ... -Trading Markets, Independent Analysis of EORTC Trial Confirms Survival Impact of ...  Sep 19, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -PR Newswire

Genta's Down, but Is it Out?  Sep 8, 2006
In 2004, a similar thumbs-down vote from an advisory panel (regarding the use of a combination therapy of Genasense plus dacarbazine for the treatment of ... -MSNBC

Weekly Wrap-up - Pharma Sector: Genta's Genasense Gets Knockout ...  Sep 10, 2006
The company's woes have been confounded by the rejection of its combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced ... -Trading Markets

Genta Says FDA Has Published Briefing Documents For ODAC Review Of ...  Sep 5, 2006
Authorization Application to the European Medicines Agency (EMEA | charts | news | PowerRating) for use of Genasense plus dacarbazine for treatment of patients ... -Trading Markets

Genasense(R) Trial in Chronic Lymphocytic Leukemia Shows ...  -  Dec 11, 2006
Drug Newswire (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane ...  -  Nov 29, 2006
PR Newswire (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,In 2004, the FDA advisory panel voted down the use of a combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced

Genta Incorporated Announces Second Quarter 2006 Financial Results ...  Aug 8, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -PR Newswire

Genta Announces Resignation of Jerome Groopman, MD from the Board ...  22 Jul 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -Yahoo! News

Special Protocol Assessment for Ipilimumab in Melanoma  Jun 30, 2006
...of a registrational clinical trial evaluating ipilimumab (MDX-010) for use as first-line treatment, in combination with dacarbazine, for metastatic melanoma. ... -Cancer Consultants

New Orphan Drug Indication for Amplimexon™  Jun 30, 2006
Amplimexon is currently in phase I-II studies evaluating its effectiveness in combination with dacarbazine for the treatment of melanoma, and Gemzar ... -Cancer Consultants



Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - Genetic Engineering News





Genasense(R) Mechanisms of Action with Chemotherapy and Radiation ...  Apr 5, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire

Genta Incorporated Announces Fourth Quarter and Year End 2005 ...  Mar 10, 2006
Genta completed submission of its Marketing Authorization Application (MAA) for Genasense plus dacarbazine for treatment of patients with advanced melanoma. ... - PR Newswire

Genta Receives Designation as a Small/Medium Enterprise by the ...  Mar 16, 2006
SME designation.". The MAA proposes the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. Summary ... - Yahoo! News

Genta Receives Designation as a Small/Medium Enterprise by the ...  Mar 16, 2006
MAA, and we greatly appreciate the assistance accorded us with the SME designation." The MAA proposes the use of Genasense plus dacarbazine for treatment of ... - PR Newswire

Randomized Trial Shows Ganite(R) Effective When Compared with a ...  Mar 2, 2006
Genta has also submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire,

Highlights of rising and falling US stocks  Feb 2, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, the Berkeley Heights, NJ-based ... - Investor's Business Daily (subscription)

Genta Incorporated to Present in Roundtable and Corporate Sessions ...  Feb 7, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire

Genasense(R) Marketing Authorization Application in Melanoma ...  Feb 1, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, particularly for patients for ... - PR Newswire

Highlights of rising and falling US stocks  Feb 2, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, the Berkeley Heights, NJ-based ... - Investor's Business Daily (subscription)

International Approvals: Tasmar, Amplimexon, IV Remodulin  Jan 17, 2006
1/2 clinical studies in combination with gemcitabine for the first-line treatment of advanced pancreatic adenocarcinoma; with dacarbazine for the treatment of ... - Medscape (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional